🎉 M&A multiples are live!
Check it out!

Novavax Valuation Multiples

Discover revenue and EBITDA valuation multiples for Novavax and similar public comparables like CSL, AstraZeneca India, and Prescient Therapeutics.

Novavax Overview

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.


Founded

1987

HQ

United States of America
Employees

952

Website

novavax.com

Financials

LTM Revenue $680M

LTM EBITDA -$121M

EV

$338M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Novavax Financials

Novavax has a last 12-month revenue of $680M and a last 12-month EBITDA of -$121M.

In the most recent fiscal year, Novavax achieved revenue of $682M and an EBITDA of -$108M.

Novavax expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Novavax valuation multiples based on analyst estimates

Novavax P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $556M $682M XXX XXX XXX
Gross Profit $696M $213M XXX XXX XXX
Gross Margin 125% 31% XXX XXX XXX
EBITDA -$487M -$108M XXX XXX XXX
EBITDA Margin -88% -16% XXX XXX XXX
Net Profit -$658M -$545M XXX XXX XXX
Net Margin -118% -80% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Novavax Stock Performance

As of April 15, 2025, Novavax's stock price is $6.

Novavax has current market cap of $1.0B, and EV of $338M.

See Novavax trading valuation data

Novavax Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$338M $1.0B XXX XXX XXX XXX $-0.69

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Novavax Valuation Multiples

As of April 15, 2025, Novavax has market cap of $1.0B and EV of $338M.

Novavax's trades at 0.5x LTM EV/Revenue multiple, and -2.8x LTM EBITDA.

Analysts estimate Novavax's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Novavax and 10K+ public comps

Novavax Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $338M XXX XXX XXX
EV/Revenue 0.5x XXX XXX XXX
EV/EBITDA -3.1x XXX XXX XXX
P/E -5.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -3.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Novavax Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Novavax Valuation Multiples

Novavax's NTM/LTM revenue growth is -7%

Novavax's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Novavax's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Novavax's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Novavax and other 10K+ public comps

Novavax Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 23% XXX XXX XXX XXX
EBITDA Margin -16% XXX XXX XXX XXX
EBITDA Growth -78% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -22% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 57% XXX XXX XXX XXX
Opex to Revenue 107% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Novavax Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Novavax M&A and Investment Activity

Novavax acquired  XXX companies to date.

Last acquisition by Novavax was  XXXXXXXX, XXXXX XXXXX XXXXXX . Novavax acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Novavax

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Novavax

When was Novavax founded? Novavax was founded in 1987.
Where is Novavax headquartered? Novavax is headquartered in United States of America.
How many employees does Novavax have? As of today, Novavax has 952 employees.
Who is the CEO of Novavax? Novavax's CEO is Mr. John C. Jacobs.
Is Novavax publicy listed? Yes, Novavax is a public company listed on NAS.
What is the stock symbol of Novavax? Novavax trades under NVAX ticker.
When did Novavax go public? Novavax went public in 1995.
Who are competitors of Novavax? Similar companies to Novavax include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of Novavax? Novavax's current market cap is $1.0B
What is the current revenue of Novavax? Novavax's last 12-month revenue is $680M.
What is the current EBITDA of Novavax? Novavax's last 12-month EBITDA is -$121M.
What is the current EV/Revenue multiple of Novavax? Current revenue multiple of Novavax is 0.5x.
What is the current EV/EBITDA multiple of Novavax? Current EBITDA multiple of Novavax is -2.8x.
What is the current revenue growth of Novavax? Novavax revenue growth between 2023 and 2024 was 23%.
Is Novavax profitable? Yes, Novavax is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.